Q-omics provides the consensus-scored ZNF843 profile across patient tissues and cancer cell-line models. ZNF843 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF843 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ZNF843 RNA expression shows 18,709 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where ZNF843 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF843 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF843 survival associations across molecular data types. ZNF843 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF843 RNA expression–survival associations across cancer types. High ZNF843 expression shows unfavorable associations in THCA, but favorable associations in KIRC, UVM, LGG, ACC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF843 RNA expression.
This table summarizes ZNF843 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF843. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF843 shows lower tumor expression in KICH, THCA, UCEC, BRCA and KIRC and higher tumor expression in LIHC. The KICH box plot shows higher ZNF843 RNA expression in normal versus tumor tissue (log2 FC = −0.772, t-test p < 0.001).
This table shows molecular features associated with ZNF843 in patient tissues and cancer cell lines. In patient samples, ZNF843 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF843 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
